Similarly, by comparing RNF43-mutant patients across tumor stages, the platform revealed a significant survival disadvantage in metastatic cases, a finding that would otherwise require multi-step analyses in standard bioinformatics tools. This evidence concerns the gene RNF43 and neoplasm.